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Abstract  !
New targeted approaches to ovarian clear cell carcinomas (OCCC) are 
needed, given the limited treatment options in this disease and the poor 
response to standard chemotherapy. Using a series of high-throughput cell 
based drug screens in OCCC tumor cell models, we have identified a 
synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and a 
key driver in OCCC, ARID1A mutation. Imposing ARID1A deficiency upon a 
variety of human or mouse cells induced dasatinib sensitivity, both in vitro and 
in vivo, suggesting that this is a robust synthetic lethal interaction. The 
sensitivity of ARID1A deficient cells to dasatinib was associated with G1/S cell 
cycle arrest and was dependent upon both p21 and Rb. Using focused siRNA 
screens and kinase profiling, we showed that ARID1A mutant OCCC tumor 
cells are addicted to the dasatinib target, YES1. This suggests that dasatinib 
merits investigation for the treatment of patients with ARID1A mutant OCCC. 
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Introduction  
Ovarian clear cell carcinomas (OCCC) comprise between 5 and 25% of all 
epithelial ovarian cancers and are often associated with endometriosis (1). 
Patients with advanced OCCC generally respond poorly to standard platinum 
based chemotherapy and have a median five-year survival rate of less than 
32 % (2, 3). Recently, comprehensive DNA sequencing of OCCCs has led to 
the identification of likely driver mutations in this disease (4, 5). The most 
commonly recurrent genetic event in OCCC is somatic mutation in the tumour 
suppressor gene ARID1A (AT-Rich Interactive Domain-containing protein 1A) 
which are present in up to 57% of patients (4, 5). A significant proportion of 
the tumour-associated somatic ARID1A mutations in OCCC are frame-shift 
insertion/deletion mutations or nonsense mutations that are predicted to result 
in premature truncation of the protein (4, 5). In addition to being recurrently 
mutated in OCCC, frame-shift insertion/deletion mutations and nonsense 
mutations in ARID1A have also been identified in multiple other cancer types 
such as gastric cancer, renal clear cell cancer and pancreatic tumours (6). 
Loss of ARID1A expression has also been associated with a shorter 
progression free survival and resistance to platinum based chemotherapy in 
OCCC patients (7). 
 
The best-characterised role of the ARID1A protein is as a component of the 
BAF SWI/SNF chromatin-remodeling complex. The BAF complex plays a key 
role in modifying the position of nucleosomes on DNA (8-10) and in doing so 
likely regulates the access of additional proteins to DNA (8). The composition 
of the BAF complex includes: (i) an ATP dependent DNA helicase, encoded 
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by the SMARCA4/BRG1 or SMARCA2/BRM genes; (ii) ARID1A or ARID1B, 
which each encompass an ARID DNA binding domain; and (iii) a series of 
additional accessory subunits such as SMARCB1, SMARC1 and 2, 
SMARCD1-3, SMARCE1, ACTL6A and DFP1-3 (8, 11). ARID1A dysfunction 
has been associated with a relatively diverse set of phenotypes including 
defects in cell differentiation, alterations in the control of cell proliferation as 
well as defects in the repair of DNA (9, 10, 12, 13). However, a precise 
molecular understanding of how defects in ARID1A lead to each of these 
phenotypes is not yet clear.  
 
Given the high prevalence of ARID1A mutations in OCCC, identifying drugs 
that selectively target ARID1A mutant tumour cells could potentially inform the 
development of new therapeutic approaches to this disease. Recently the 
methyltransferase, EZH2 and PARP inhibitors have been proposed as 
therapeutic targets in ARID1A mutant tumours (14, 15) and synthetic lethality 
between ARID1A and ARID1B has also been described (16). Here, we 
describe a high-throughput functional genomics approach to screen a series 
of clinically used drugs with the intention of identifying novel ARID1A synthetic 
lethal effects (17) that operate in OCCC. By profiling drugs that are either 
already used in the clinical management of cancer or compounds with targets 
that are currently in late-stage development, we also aimed to identify 
ARID1A synthetic lethal approaches that could potentially be rapidly 
translated in the clinic. 
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Materials and Methods  
 
 
Reagents and cell lines 
Dasatinib was purchased from Selleck chemicals. Additional drugs and small 
molecule inhibitors used in this study are listed in Supplementary Table S1. 
ES2 and TOV21G were obtained from the American Type Tissue Collection. 
RMG-1, SMOV2, KOC7C, HCH1, OVAS, OVISE, OVMANA, OVTOKO and 
KK were provided by Dr. Hiroaki Itamochi (Tottori University School of 
Medicine, Yonago, Japan). Ovarian clear cell lines were grown in RPMI with 
10% FCS. The identity of cell lines was confirmed by STR typing using the 
StemElite Kit (Promega) in March 2013 and where appropriate, profiles were 
confirmed using the Children's Oncology Group (COG) Cell Culture and 
Xenograft Repository bank (http://strdb.cogcell.org) or JCRB cell bank 
(http://cellbank.nibio.go.jp). ARID1A HCT116 were grown in McCoys media 
with 10% (v/v) FCS. Arid1a null and wild-type mouse embryonic stem cells 
were provided by Dr Zhong Wang (Harvard Medical School, USA) (9) and 
grown on gelatin coated plates in DMEM with 10% (v/v) FCS supplemented 
with 0.1 mM non essential amino acids, 1 mM sodium pyruvate, 0.1 mM beta-
metcaptothanol and 2000U LIF/ml.  All cell lines were routinely confirmed as 
being mycoplasma negative using the MycoAlert Kit (Lonza) throughout 
experimentation. 
 
High throughput drug screen 
Cell lines were profiled using a customised drug library (Supplementary 
materials and methods) containing 68 compounds (Supplementary Table S2 
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and Supplementary Table S3). Cells were plated at a density of 250 or 500 
cells per well. 24-hours later, media containing drug library was added to 
adherent cells. On day seven, cell viability in each well was estimated using 
CellTiter-Glo (Promega). Luminescence data was log2 transformed and 
centred on a per plate basis according to the plate median value. Z prime 
>0.3 and r2 >0.75 were used to define acceptable screen data. Where 
appropriate, surviving fractions were calculated relative to DMSO treated 
wells and this data was used to generate AUC (area under the curve) and 
SF50 data.  
 
Cell-based assays 
Short-term drug exposure assays were performed in 96 well plates. Cells 
were plated at a density of 250-500 cells/ well and drug added at the indicated 
concentration 24 hours later. Cell viability was estimated after seven days 
using Cell-Titre Glo (Promega). Surviving fractions (SFs) were calculated 
relative to DMSO treated wells, and drug sensitivity curves plotted.  
 
Clonogenic assays were performed in triplicate in 6 well plates. OCCC cell 
lines were plated at a density of 500 cells/well and mouse ES cells were 
plated at a density of 2000 cells per well on gelatin-coated plates. Media 
containing dasatinib at the indicated concentrations was replaced every three 
days. After 14 days, cells were fixed in 10% trichloroacetic acid and stained 
with sulforhodamine-B prior to counting.  
 
siRNA experiments 
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A 384 well plate arrayed siRNA library targeting 784 genes (Dharmacon) was 
used (gene list described in Supplementary Table S4) or a bespoke 
Dharmacon siRNA library of dasatinib targets. Each well either contained a 
SMART pool (four distinct siRNA species targeting different sequences of the 
target transcript combined) or a single siRNA species. Additional positive 
(siPLK1) and negative (siCON1, siCON2 and Allstar (Dharmacon and Qiagen, 
respectively)) controls were also added to each plate. Cells were reverse 
transfected using Dharmafect4 (Dharmacon). 48 hours following transfection, 
media containing with dasatinib or the drug vehicle, DMSO, was added to the 
plates. After seven days, cell viability in each well was estimated using a 
CellTitre-Glo assay. Data was processed as described in supplementary 
materials and methods and as in (18). 
 
Dasatinib Bead Proteomics 
Inhibitor bead proteomics was performed as previously described (19, 20). 
Dasatinib was covalently linked to ECH sepharose 4B using EDC and then 1 
mg of pre-cleared cell lysate was rotated with 50 mL of dasatinib bead slurry 
for three hours. Beads were washed twice with cold binding buffer and then 
an additional three times with binding buffer with reduced NaCl minus 
detergent. Proteins were eluted with 6 M urea and trypsinised, desalted and 
analysed by LC-MS/MS on a Thermo LTQ Orbitrap Velos. Spectra were 
searched using Protein Prospector and label free quantitation performed with 
Skyline. Significance of effects was determined using MS Stats (21). 
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Protein analysis 
Cells were lysed, electrophoresed and immunoblotted as described previously 
(22). We used the following antibodies: ARID1A (Bethyl A301-040A [human] 
and Santa Cruz sc-32761 [mouse]) -Actinin (A5044, Sigma), Actin (sc-1616 
Santa Cruz), -Tubulin, (2146, cell signaling), YES1 (3201S Cell Signaling) 
and CDKN1A (2947 Cell Signaling). All secondary antibodies were 
horseradish peroxidase conjugated. Primary antibodies were used at a 
concentration of 1:1000 and secondary antibodies at a concentration of 
1:10000. Protein bands were visualised using enhanced chemiluminescence 
(ECL, GE Healthcare, UK) and Kodak BioMAX XAR film (Kodak). Alternatively, 
lysates were probed with the primary antibody and a fluorescent-dye labeled 
secondary antibody and images were taken using the Odyssey Infrared 
Imaging system from Licor ®. 
 
Exome sequencing 
BWA (Burrows-Wheeler Aligner, bio-bwa.sourceforge.net ) was used to align 
short reads to a reference sequence (GRCh37). Duplicate sequence reads 
(PCR-derived duplicates) were removed from further analysis at this point. 
Base quality recalibration, realignment around indels, and variant calling were 
performed using the Genome Analysis Tool Kit (GATK) using the Broad best 
practice variant detection workflow (www.broadinstitute.org/gatk/guide/best- 
practices). Small insertions and deletions detected in the tumour cell lines that 
were absent in the reference genomes were considered to be candidate 
somatic mutations. The set of candidate somatic mutations was refined using 
the following list of heuristic rules: (i) variants called in regions not covered by 
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the exome capture probes were excluded; (ii) variants marked as low quality 
(QUAL below 20) were excluded; (iii) variants with fewer than 10 reads 
covering the locus in all samples were excluded. Common SNPs (those 
reported to have a global minor allele frequency of greater than 5% in any of 
the 1000 genomes project data sets) were also removed from the main 
analysis. The remaining variants were annotated using the Ensembl variant 
effect predictor script (Ensembl v61). 
 
Cell cycle analysis 
Cells were plated at a density of 2 x 106 cells per well of a six well plate and 
incubated for 24 hours after which dasatinib or 0.1% (v/v) DMSO was added 
to the media and cells cultured for a further 24 hours. After incubation, both 
adherent and free-floating cells were harvested and then fixed overnight with 
cold 70% (v/v) ethanol. Cells were then treated with RNase A for 30 mins prior 
to nucleic acid staining with propidium iodide (PI, Sigma). Samples were 
analyzed on a BD LSR II flow cytometer using BD FACSDiva software (BD 
Biosciences).  
 
Apoptosis assay 
After 48 hours dasatinib exposure, cells were analysed using the ApoTox-
Glo™ Triplex Assay (Promega) as per the manufacturer’s instructions.   
 
In vivo efficacy studies 
For the biomarker study, TOV21G cells were used to generate subcutaneous 
xenografts in nu/nu athymic female mice. Once tumours were established (≥ 
500 mm diameter), treatment with dasatinib was initiated for 72 hours. 
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Dasatinib was either dissolved in 80 mM sodium citrate at pH 3 for 
administration via oral gavage or dissolved in DMSO for intraperitoneal 
injections. Three animals received oral dasatinib at a dose of 15, 30 or 45 
mg/kg/day and three animals IP dasatinib at a dose of 5, 10 or 15 mg/kg/day, 
the remaining animal served as a control and was not treated. Two hours 
following the final drug administration animals were culled; tumour and normal 
tissue (spleen and liver) were then collected. Tissue was then thinly sliced 
and mixed with RIPPA buffer in a cryotube overnight at 4oC. Samples were 
then homogenized and spun in a centrifuge at 15,000 rpm for 15 minutes. The 
supernatant was then removed and protein quantified using Biorad Protein 
Assay Reagent (BioRad, Hemel Hempstead, UK). 
 
TOV21G cells were transfected with a luciferin expression lentivirus (LVP433 
Amsbio) and maintained in blasticidin selection (25 ug/ml) for ten days prior to 
injection into female athymic nu/nu mice. 1.0 x106 TOV21G cells in 100µl of 
PBS were injected directly into the peritoneal cavity of 40 nu/nu athymic 
female mice. Treatment with dasatinib (n=20) or vehicle (n=20) was initiated 
24 hours following tumour injection. Mice received either dasatinib 15 mg/kg 
in sodium citrate (80mM) via oral gavage or vehicle treatment (sodium citrate) 
daily. Prior to IVIS imaging luciferin 150 mg/kg  (Perkineliner) was injected 
into the peritoneum. Mice were culled when they exhibited signs of distress or 
> 20% weight loss or gain (secondary to ascites). 
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Results  
 
Identification of ARID1A selective drugs using a focused drug screen 
We aimed to identify existing drugs that could selectively target ARID1A 
mutant OCCC. To do this, we designed a high-throughput drug sensitivity 
screen (Figure 1A), where we profiled the in vitro sensitivity of a range of 
tumour cell models of OCCC to 68 drugs many of which are currently used in 
the treatment of cancer or are in late stage development. To facilitate this, we 
first characterised a panel of commonly used OCCC tumour cell models 
according to their ARID1A gene mutation and protein expression status. 
Using whole exome sequencing and immunoblot analysis, we confirmed the 
previously documented (23, 24) presence of truncating ARID1A mutations 
and loss of full length ARID1A protein expression in SMOV2, OVISE, 
TOV21G, OVTOKO, OVMANA, KOC7C, OVAS and HCH1 OCCC cell line 
models (Supplementary Figures S1A-B, S2 and Supplementary Table S5). 
We also confirmed the expression of full length ARID1A protein and the 
absence of ARID1A gene mutations in ES2, KK and RMG-1 models of OCCC 
(Supplementary Figure S1A-B, S2 and Supplementary Table S5). This 
characterisation allowed us to define two cohorts of OCCC tumour cell models 
for further analysis: ARID1A mutant (deficient) (SMOV2, OVISE, TOV21G, 
OVTOKO, OVMANA, KOC7C, OVAS and HCH1) and ARID1A wild type (ES2, 
KK and RMG-1). 
 
Using these OCCC tumour cell lines, we carried out a series of parallel high-
throughput drug sensitivity screens (HTS). As a screening library, we used an 
in-house curated collection of 68 drugs that were selected on the basis of 
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being either already used in the treatment of cancer or being in late stage 
development (Supplementary Table S2). Each tumour cell line was plated in a 
384-well plate format and then 24-hours later, exposed to each drug for a 
subsequent five days. At the end of this five-day period, we estimated cell 
viability by the use of a CellTitreGlo (CTG) assay (Figure 1A). Each of the 11 
OCCC tumour cell lines was screened in triplicate, with replica drug sensitivity 
data from each cell line being highly reproducible as shown by Pearson’s 
correlation coefficients between screen replicas of > 0.75 (Figure 1B and 
Supplementary Table S6). The dynamic range of each screen was also 
estimated by calculating Z prime (Z’) values for data from each 384 well plate 
used in the screen. To calculate Z’ values we compared CTG luminescent 
readings from DMSO (cell inhibition negative control) exposed cells to CTG 
luminescence readings from wells where cells were exposed to 5 µM 
puromycin (cell inhibition positive control). Each 384 well plate in the screen 
delivered a Z’ > 0.5 (Figure 1C and Supplementary Table S6), confirming a 
suitable dynamic range for each plate used in the screen. To maximise the 
potential for identifying ARID1A synthetic lethal effects, we screened each cell 
line using four different drug concentrations (1 nM, 10 nM, 100 nM and 1 µM) 
and used this data to generate dose/response survival data for each drug in 
each cell line model (Supplementary Table S7). This data was then used to 
calculate area under the curve values (AUC) for each drug in each tumor cell 
line as well as SF50 (Surviving Fraction 50 – the concentration of drug 
required to elicit a 50% inhibition of the cell population) estimates of drug 
sensitivity (Supplementary Figure S3A, B) of each OCCC tumour cell line. 
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By comparing the median AUC values in ARID1A wild type and mutant 
cohorts, we identified drugs predicted to deliver an ARID1A mutant selective 
effect. The most profound effect identified in this way was elicited by dasatinib 
(BMS-354825 – Figure 1D,E). When defining the differential drug sensitivities 
in ARID1A mutant vs. wild type cohorts by comparing median AUC values, 
dasatinib showed a distinct effect, with an AUC of 4 x 10-6 in the ARID1A 
mutant cohort vs. 1 x 10-5 in the ARID1A wild type cohort (Figure 1D,E), an 
effect also observed by the comparison of dasatinib SF50 data (Figure 1 F,G). 
Finally, by using an ANOVA calculation to assess the overall difference in 
surviving fraction across the 1 nM - 1 µM dasatinib concentration range used 
in the screen, we found the ARID1A mutant cohort to have a significantly 
lower survival that the ARID1A wild type cohort (p<0.0001, ANOVA). In 
addition to dasatinib, we also noted that drugs such as everolimus caused 
moderate ARID1A selective effects in the drug screen (Supplementary Table 
S7, Supplementary Figure S3A). Elements of the PI3K/mTOR signaling 
cascade have recently been shown to be constitutively active in ARID1A 
mutant endometrial and OCCC cancers (25-27), suggesting that ARID1A 
mutant tumours might be addicted to PI3 kinase signaling (28). On the basis 
of this earlier work and our screen data we assessed these moderate ARID1A 
selective effects in subsequent validation experiments (Supplementary Figure 
S4). These confirmed that ARID1A mutant tumour cell line models were 
modestly more sensitive to drugs such as the everolimus, but these effects 
were not as profound as those caused by dasatinib (Supplementary Figure 
S4). 
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Dasatinib is a synthetic lethal drug in ARID1A mutant OCCC tumour cell 
line models 
To validate the ARID1A selectivity of dasatinib identified in the high-
throughput screens, we carried out both short-term as well as long-term drug 
sensitivity experiments in our panel of OCCC tumour cell lines. We found that 
a relatively short six-day exposure to dasatinib was selective for ARID1A 
mutant OCCC models (Figure 2A,B, Supplementary Figure S5A-B, two-way 
ANOVA ARID1A mutant vs. wild-type cohorts p<0.05) as was a longer-term, 
15-day drug exposure (Figure 2C,D, Supplementary Figure S5C-D, two-way 
ANOVA ARID1A mutant vs. wild-type cohorts in Figure 2C p<0.0001).  
 
Although we found dasatinib to preferentially target the ARID1A mutant cohort 
of OCCC models, the possibility existed that other genetic variants in the 
tumour cell line panel might explain the sensitivity to dasatinib. To 
independently establish whether ARID1A was indeed a determinant of 
dasatinib sensitivity, we assessed drug sensitivity in three different isogenic 
model systems in which we engineered either ARID1A depletion or mutation. 
In the first instance, we exploited the previously validated mouse ES cell 
model of Arid1a deficiency (Figure 2E and Supplementary Figure S2) 
generated by Gao and colleagues (9), where both alleles of Arid1a were 
rendered dysfunctional by gene targeting. We found dasatinib to be selective 
for the Arid1a null ES cell model, compared to the wild type clone, consistent 
with the hypothesis that ARID1A is a determinant of dasatinib sensitivity 
(p<0.0001 two-way ANOVA, Figure 2F). We also used gene silencing to 
suppress ARID1A expression in the two ARID1A wild-type, dasatinib resistant, 
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human OCCC models and ARID1A wild-type breast cancer and colorectal 
cancer cell lines models (Figure 2G, H and Supplementary Figures S2, S5E-
G). Not only did the siRNA SMARTpool designed to target ARID1A elicit 
dasatinib sensitivity in the ARID1A wild-type OCCC cell lines but this was also 
caused by multiple independent ARID1A siRNA species (Figure 2G,H), 
suggesting that this was unlikely to be an off target effect of the RNA 
interference reagents used.  
 
In addition to these two systems of ARID1A perturbation, we also generated 
an isogenic human colorectal tumour cell model (HCT116) in which both 
copies of the ARID1A gene were inactivated by a p.Q456* truncating mutation. 
This model was generated by AAV-mediated somatic gene targeting (29). As 
expected, mutation of both copies of ARID1A (Supplementary Figure S6A) 
caused loss of full length ARID1A expression (Supplementary Figures S2 and 
S6B). Using this model (ARID1AQ456*/Q456*) and the parental ARID1A wild type 
clone (ARID1AWT/WT), we carried out a subsequent high-throughput drug 
screen using a second compound library which included the original screening 
library with the addition of a number of supplementary drugs (Supplementary 
Table S3, Supplementary Table S8). Three different concentrations of 
dasatinib (1000 nM, 500 nM and 100 nM) were ranked within the ten most 
profound ARID1AQ456*/Q456* selective effects (Supplementary Figure S6C). 
This finding was confirmed in a subsequent validation assay (Supplementary 
Figure S6D, two-way ANOVA p<0.001 ARID1AQ456*/Q456* cells compared to 
the parental ARID1AWT/WT model).  
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Having confirmed the validity of the ARID1A/dasatinib synthetic lethality, we 
assessed whether this effect could be explained by hyperactivity and/or 
addiction to dasatinib targets. In the first instance, we used an unbiased 
activity-based proteomics approach to estimate the relative activity of all 
dasatinib-binding kinases in a subset of our OCCC panel. This “inhibitor bead” 
approach is based upon the use of an ATP-competitive kinase inhibitor (in this 
case dasatinib) covalently linked to sepharose. As the ATP-binding avidity of 
protein kinases is increased by the allosteric changes that follow kinase 
activation, the relative amount of particular kinases bound to sepharose-
dasatinib beads  (measured by mass spectrometry) can be used to estimate 
kinase activity (Figure 3A) (19, 30, 31). Using this approach, we profiled 
OVISE, KK, RMG1 and TOV21G cells and found that five dasatinib targets 
(EPHA2, MAP4K5, ABL2, YES1 and ABL1) were significantly (p<0.01) 
enriched in the ARID1A mutant cell lines compared to the wild type cells 
(Figure 3B, Supplementary Tables S9 and S10).  
 
Although this data suggested that ARID1A mutant tumour cells exhibited 
enhanced activity of a number of dasatinib targets, it did not formally confirm 
addiction to EPHA2, MAP4K5, ABL2, YES1 or ABL1. Therefore, in parallel 
with this proteomic assessment we also used a genetic approach and 
assessed the addiction of 10 OCCC tumour cell lines (three ARID1A wild type 
and seven ARID1A mutant models) to dasatinib targets (Figure 3C). We 
selected 14 dasatinib targets that have dasatinib dissociation constants (kd) of 
<1 nM (32) and are inhibited at clinically relevant concentrations (33) 
(Supplementary Table S11) and profiled each tumour cell model with this 
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library.  Using this data, we were able to calculate median NPI values for both 
the ARID1A mutant OCCC cell line cohort (SMOV2, OVISE, TOV21G, 
OVMANA, KOC7C, OVAS and HCH1) as well as the ARID1A wild type cohort 
(KK, ES2 and RMG-1) (Figure 3C). By comparing the cell inhibitory effects 
caused by each siRNA in ARID1A wild-type and mutant cohorts, we identified 
likely ARID1A synthetic lethal effects (Supplementary Table S11, Figure 3D, 
Supplementary Figure S7A). We noted that the most consistent ARID1A 
selective effect (i.e. where the ARID1A selective effect was observed with 
multiple different siRNAs) was caused by siRNA designed to target YES1 
(Figure 3D). Three of the YES1 individual siRNA species and the YES1 
siRNA SMARTpool ranked within the ten most profound ARID1A selective 
effects, as defined by the median difference in NPI (Figure 3E,F, 
Supplementary Figures S2, S7B and Supplementary Table S11). We also 
found that the YES1 siRNA SMARTpool and individual YES1 siRNAs 
selectively targeted the ARID1AQ456*/Q456* HCT116 clone, as opposed to the 
ARID1AWT/WT parental clone (Supplementary Figure S7C), suggesting that 
ARID1A mutation might indeed cause dependency upon YES1, an 
observation that could explain the sensitivity of ARID1A mutant tumour cells 
to dasatinib. We confirmed that YES1 activation was reduced at relevant 
dasatinib concentrations (Supplementary Figures S2, S7D and S7E). 
However, the addiction to YES1 in ARDI1A mutant cell lines could not be 
explained by baseline differences in expression levels between the ARID1A 
wild-type and mutant cohorts (Supplementary Figures S2 and E-F).  
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Dasatinib sensitivity in ARID1A mutant OCCC is p21 and RB dependent 
and is characterised by an apoptotic response 
 
One of the known phenotypic effects of dasatinib exposure in tumour cell lines 
is the induction of G1 cell cycle arrest followed by cell apoptosis (34-39). To 
understand whether a similar effect might explain the ARID1A/dasatinib 
synthetic lethality, we assessed cell cycle progression and the extent of 
apoptosis in two ARID1A mutant and two wild-type OCCC models. This was 
carried out using propidium iodide and annexin V staining, followed by 
Fluorescent Activated Cell Scanning (FACS). We observed a modest but 
significant increase in dasatinib induced G1 arrest in the ARID1A mutant 
models, HCH1 and OVISE compared to wild type models, ES2 and KK 
(Figure 4A, p<0.05 in each wild-type vs. mutant comparison, Student’s t-test). 
There was however a more profound apoptotic response to dasatinib in the 
ARID1A mutant models suggesting that although a cell cycle response could 
form part of the dasatinib effect, apoptosis might also play a role in the cell 
growth inhibition observed (p-values for ARID1A mutant cells [OVISE and 
TOV21G] cells versus ARID1A wild-type [ES2 and KK] p<0.05 Student’s t-test, 
Figure 4B and Supplementary Figure S8).  
 
To further investigate what the key determinants of the ARID1A/dasatinib 
synthetic lethality might be, we used a synthetic rescue genetic screen to 
identify genes which when inactivated drove dasatinib resistance in ARID1A 
null OCCC models. To do this, we transfected the ARID1A mutant (p.542fs), 
dasatinib sensitive (SF50 = 23 nM) OVISE OCCC model with a siRNA library 
targeting 784 genes, predominantly protein kinase coding genes, and 
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assessed whether we could induce dasatinib resistance. OVISE cells were 
reverse transfected in 384-well plates containing the siRNA library. In total, 
nine replica transfections were performed. Forty-eight hours after siRNA 
transfection cells were exposed to either 25 nM dasatinib (three replicates), 
120 nM dasatinib (three replicates) or the drug vehicle DMSO (three 
replicates). Cells were then continuously exposed to drug for five days after 
which cell viability was estimated by use of a CellTitreGlo (CTG) assay. In 
cells transfected with a control non-targeting siRNA (siCON), exposure to 25 
nM dasatinib resulted in a Surviving Fraction of 50% (SF50), whereas 
exposure to 120 nM dasatinib resulted in a SF on 16% (SF16). The effect of 
each siRNA on dasatinib resistance was then estimated by calculating drug 
effect (DE) Z scores ((18) and see Materials and Methods) with positive DE Z 
scores representing resistance causing effects. For each gene, the DE Z 
scores at 25 and 125 nM dasatinib were calculated and rank ordered (Figure 
5A and Supplementary Table S12). By calculating the average DE Z scores 
from both SF50 and SF16 screens, we identified those siRNAs that elicited the 
most robust dasatinib resistance-causing effects.  
 
Using this relatively unbiased approach, we found the most profound 
dasatinib resistance causing effects in both SF50 and SF16 screens to be 
caused by siRNAs targeting the key G1/S cell cycle regulators CDKN1A (p21) 
and RB1 (DE Z scores of 4.41 and 4.96 respectively, Figure 5A). Dasatinib 
has been shown to increase the expression of p21, the protein encoded by 
CDKN1A, as well as enhancing the protein expression of another cyclin 
dependent kinase inhibitor, p27 (34, 36, 38-41). Considering this, as well as 
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the results from the synthetic rescue screen described above, we assessed 
whether the dasatinib/ARID1A synthetic lethality could be reversed by 
inactivation of CDKN1A or the downstream mediator, RB1. We found that an 
siRNA pool designed to target CDKN1A reversed the dasatinib/ARID1A 
synthetic lethality in the ARID1A mutant OCCC cell line OVISE but had 
negligible effects in an ARID1A wild-type model ES2 (Figure 5B and 
Supplementary Figure S9A). In order to confirm that the dasatinib resistance 
observed was due to CDKN1A silencing and not an off-target effect, three 
individual siRNA species and the SMARTpool were transfected into two 
ARID1A mutant OCCC cell lines and the ARID1A isogenic clones. 
Transfection of each individual siRNA and the SMARTpool led to dasatinib 
resistance in both of the cell lines examined suggesting an on-target effect 
(Figure 5C) and western blot analysis confirmed CDKN1A silencing (Figure 
5D and Supplementary Figure S2). We also found that silencing of RB1, a key 
modulator of the G1/S checkpoint also caused dasatinib resistance in multiple 
ARID1A mutant OCC cell lines and the isogenic HCT116 ARID1A Q456*/Q456* 
clone (Supplementary Figures S2 and S9B-E), supporting the hypothesis that 
in ARID1A null tumour cells, the inhibitory effect of dasatinib is mediated via 
the activity of CDKN1A and RB1.  
 
Dasatinib is selective for ARID1A mutant OCC tumours in vivo 
 
We generated an in vivo model of ARID1A mutant OCCC by subcutaneously 
xenografting the TOV21G ARID1A mutant OCCC cell line (ARID1A 
p.548fs/p.756fs) into immunocompromised recipient mice. This led to the 
growth of very aggressive, highly proliferative, subcutaneous tumours. This 
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approach allowed us to assess the effect of dasatinib on these tumours. 
Published reports on the use of dasatinib in mice vary greatly in terms of the 
route of administration (oral gavage or intraperitoneal (IP) injections) as well 
as in the dasatinib dose used (42-44). Therefore, to identify a dose and route 
of administration that would minimize the impact of deleterious side effects 
whilst still delivering an effective dose, we first conducted a biomarker study. 
Subcutaneous TOV21G tumours were established in nu/nu athymic mice and 
animals were treated with dasatinib using either oral gavage or intra-
peritoneal (IP) routes of administration at a range of concentrations (oral 
administration of 15, 30 or 45mg/kg per day or IP administration of 5, 10 or 15 
mg/kg per day). By estimating the extent of SRC phosphorylation as a 
biomarker of dasatinib activity, we were able to predict whether dasatinib 
elicited a mechanistic effect in both tumour and normal tissue (Supplementary 
Figure S10). At each dasatinib dose tested and using ether oral or IP 
administration, SRC phosphorylation was completely abolished in both tumour 
and normal tissue (Supplementary Figure S10) and was well tolerated in each 
case. We therefore selected the lowest dose of dasatinib (15 mg/kg) for 
subsequent studies and administered this via an oral route.  
 
Based on this data, we assessed the in vivo anti-tumour efficacy of dasatinib. 
To do this, we first labeled ARID1A mutant TOV21G cells with a luciferase-
expressing construct so that we could later visualize the extent of tumour 
burden in live animals by the use of an In Vivo Imaging System (IVIS, 
PerkinElmer). These labeled cells were then xenografted into recipient mice 
where they generated widespread miliary (disseminated) peritoneal disease 
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and ascites formation, reminiscent of the clinical scenario in OCCC (Figure 
6A). Treatment of these mice with dasatinib led to a significant reduction in 
TOV21G-related luminescence (Figure 6A-B p< 0.01 two-way ANOVA), 
suggesting a therapeutic response. This effect was also reflected in an 
increase in overall survival in the dasatinib treated cohort of mice (p=0.004 
Mantel Cox test).  
 
Discussion 
Ovarian cancer is the most lethal gynaecological malignancy. The OCCC 
subtype presents a particular clinical management challenge as it is invariably 
characterised by resistance to standard chemotherapy as well as a poor 
prognosis (1). In the work presented here, we have attempted to understand 
drug sensitivities associated with ARID1A mutation in OCCC by using a 
functional genomics approach. This has led us to the identification of dasatinib 
as a candidate synthetic lethal drug in ARID1A mutant OCCC. Dasatinib is not 
only selective for ARID1A mutant OCCC models, but experimental induction 
of ARID1A deficiency drives dasatinib sensitivity in ARID1A wild type OCCC 
models as well as in isogenic cell systems (both mouse and human) where 
ARID1A has been rendered dysfunctional by gene targeting. The selectivity of 
dasatinib in this context appears to be characterized by a cell cycle 
arrest/apoptotic phenotype, which can be reversed with silencing of either 
CDKN1A or RB1.  
 
ARID1A has previously been demonstrated to act as a negative regulator of 
the cell cycle (10, 24, 45). In part this effect has been ascribed to an 
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impairment of p21 mediated cell cycle control in ARID1A null cells (24). 
Taking this into account, along with the data presented here, and the known 
role of dasatinib in p21 induction (34, 36, 46), one possibility is that dasatinib 
targets ARID1A mutant tumour cells because it reverses p21 dysfunction 
caused by ARID1A deficiency. The work presented here suggests that the 
dasatinib sensitivity of ARID1A null models is somewhat dependent upon p21 
and RB1, observations that are consistent with this hypothesis. It is possible 
that the sensitivity to dasatinib might be related to a dependency upon the 
dasatinib target YES1 that we have observed, although we cannot discount 
the possibility that other dasatinib targets might also be involved or that 
combinations of dasatinib targets might play a role in the phenotype we 
observe. We do note that an analysis of microarray–based mRNA profiles 
from the ARID1A wild type and mutant tumour cell lines described in this 
report and publically available transcriptomic profiles of ARID1A mutant 
OCCC did not identify a canonical signaling process that was distinct between 
wild type and mutant cohorts (RM, CJL, AA, unpublished observations). 
Although the correlation between ARID1A genotype and dasatinib sensitivity 
are striking, being present in not only in the panel of OCCC models but also in 
isogenic systems, we noted that one of the ARID1A mutant OCCC cell lines, 
KOC7C, was relatively resistant to dasatinib but addicted to YES1. It is 
possible that whilst the ARID1A defect in KOC7C is sufficient to drive YES1 
addiction, other genetic or epigenetic factors in this cell line modulate the 
ARID1A/dasatinib synthetic lethality. 
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Our assessment of dasatinib efficacy suggests that there are promising signs 
that dasatinib can inhibit ARID1A mutant tumours in vivo, although it is clear 
that further work is required to optimise how dasatinib might be used to elicit a 
profound, long-lasting anti-tumour response in women with ovarian clear cell 
carcinomas. For example, using additional OCCC cell lines (both ARID1A wild 
type and mutant) as established orthotopic tumours (as opposed to non-
established tumours shown in Figure 6) would extend the observations made 
using the TOV21G model. It also seems reasonable to suggest that 
combination therapy approaches involving dasatinib might be used to 
maximise the therapeutic window as well as minimising the impact of 
signalling feedback loops that might impair the therapeutic effect of dasatinib. 
In this regard, one clear objective for future in vivo assessment will be to 
assess the possibility that the therapeutic window caused by dasatinib could 
be enhanced by combining this kinase inhibitor with other proposed ARID1A 
synthetic lethal drugs such as EZH2 and PARP inhibitors (14, 15). It might 
also be pertinent to assess the impact of tumour heterogeneity on the 
dasatinib therapeutic response. In this case subsequent studies assessing the 
effect of dasatinib in mice bearing ARID1A mutant human patient derived 
xenografts (PDXs) might be appropriate, given that PDX material has the 
capacity to reflect the molecular heterogeneity of human tumours.  
 
Dasatinib is already licensed for use for the treatment of chronic myelogenous 
leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic 
leukemia (AML) (47, 48). Several clinical trials have also been conducted, or 
are at least underway, in patients with solid tumours. In these solid tumour 
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clinical trials, dasatinib is being assessed either as a single agent therapy or is 
being assessed when used in combination with cytotoxic or other targeted 
therapies (49). However, to date there has been limited success in using 
dasatinib in the treatment of ovarian cancer patients. When dasatinib was 
assessed as a single agent therapy in patients with relapsed epithelial ovarian 
cancer, minimal anti-tumour activity was observed, although we note there 
were only two patients with OCCC! in this study, neither of which had known 
ARID1A status (50, 51). In a recent phase one clinical trial using dasatinib in 
combination with standard cytotoxic chemotherapy (carboplatin and 
paclitaxel), the drug combination regime could be delivered safely and some 
evidence of clinical efficacy was achieved (50, 51). Of course, neither of these 
trials were designed to test the hypothesis that ARID1A mutant OCCC might 
respond to dasatinib therapy and based upon the work we describe in this 
manuscript, we believe that testing this hypothesis is warranted. 
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Figure Legends 
 
Figure 1. Identification of ARID1A selective drugs using a focused drug 
screen (A) Focused drug high-throughput screen (HTS) schematic. Eight 
ARID1A mutant and three ARID1A wild type OCCC cell lines were plated in 
triplicate 384 well plates and twenty four hours later, media containing 
compound library was added to the 384 well plates. Cells were continuously 
cultured for a subsequent five days after which cell viability was estimated 
using a luminescence assay (CellTitre-Glo®, Promega). After processing data 
(see Materials and Methods) the screen quality control was assessed by 
examining the correlation between data from replica screens (example shown 
in B) and Z prime statistics for each plate and each screen replica (example 
shown in C). (B) Example, scatter plot of drug sensitivity data from replica 
ES2 cell line screens. (C) Example Z prime values for replica ES2 screens 
(R1= replica 1). The distribution curve on the left represents the data from 
positive control (siPLK1) and the curve on the right from negative controls 
(siCON). (D,E) Waterfall and box-whisker plots of dasatinib AUC data from 
the high-throughput screen. Median ARID1A mutant AUC = 4x106 and wild-
type = AUC 1 x105 (F,G) Waterfall (F) and box-whisker (G) plots of dasatinib 
SF50 data from the high-throughput screen. Median ARID1A mutant SF50 = 
271 nM as opposed to wild-type SF50  = 707 nM. 
 
Figure 2. Dasatinib is a synthetic lethal drug in ARID1A mutant OCCC 
tumour cell line models. (A) Median dasatinib surviving fraction (SF) dose-
response curves in ARID1A mutant and wild-type cohorts. Cells were plated 
in 96 well plates and exposed to dasatinib for five days after which SF were 
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calculated. Data in (A) represents median of six replicates per cell line. Error 
bars represent SEM. Dasatinib response in ARID1A mutant vs. wild-type 
cohort, two-way ANOVA p<0.0001. (B) Waterfall plot showing the individual 
dasatinib SF50 for each OCCC cell line (nM). (C) Clonogenic (15 day 
exposure) dasatinib response in ARID1A mutant vs. wild-type cohort, two-way 
ANOVA p<0.0001. (D) Representative clonogenic assay images from two 
ARID1A wild-type and two ARID1A mutant cell lines exposed to dasatinib  (E) 
Western blot analysis of Arid1a expression from whole cell lysates in Arid1a 
isogenic mouse ES cells. Tubulin is included as a loading control. (F) 
Dasatinib dose response survival data from clonogenic experiments in 
isogenic ES cells. Cells were plated on gelatin-coated plates and exposed to 
dasatinib for 14 days. Error bars represent SEM from six replicas per cell line. 
SF for the Arid1a null versus Arid1a wild-type mouse ES cells, two-way 
ANOVA p<0.001. (G) Dasatinib dose response survival data from the ARID1A 
wild-type cells (ES2) transfected with siRNA targeting ARID1A. 48 hours 
following transfection cells were plated into 96 well plates and exposed to 
dasatinib for five days. Error bars represent SEM from six replica experiments. 
(H) Western blot of ARID1A expression from whole cell lysates (ES2) 
transfected as described in (G). Tubulin is included as a loading control.  
 
Figure 3. ARID1A mutant cell line models and YES1 addiction  
(A) Schematic of inhibitor bead approach: active kinases are preferentially 
purified by dasatinib coupled to sepharose and analysed by LC/MS/MS. 
Label-free quantification with MS1 filtering is used to determine relative 
representation of each peptide. (B) Scatter plot of dasatinib bound kinase 
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abundance from pooled biological replicates (two each) of ARID1A wild-type 
(KK, RMG-1) and mutant (OVISE, TOV21G) tumour cell lines. Axes represent 
median centered abundance; Statistically significant ratios between ARID1A 
mutant and wild type cell lines (adjusted p <0.05) are shown in red. (C) 
Dasatinib target siRNA screen overview. Ten OCCC cell lines were included 
in the screen. Each cell line was reverse transfected with either a SMARTpool 
of four siRNAs designed or individual siRNA species (four per gene) in a 384-
well plate. The siRNA library targeted known targets of dasatinib. After siRNA 
transfection, cells were cultured for a subsequent five days at which point cell 
viability was estimated by the use of Cell Titre Glo Reagent. To estimate the 
extent by which each siRNA caused tumour cell inhibition, Normalised 
Percent Inhibition (NPI) values for each siRNA were calculated and median 
NPI values between ARID1A wild type and mutant cohorts compared. (D) 
Heatmap showing Normalised Percent Inhibition (NPI) data from the dasatinib 
target siRNA screen. Individual siRNAs are ranked according to difference in 
NPI between ARID1A mutant and wild-type cohorts. The ten most profound 
ARID1A selective are highlighted. (E) Bar chart plot of YES1 NPI values from 
the screen. Median NPI values from each cohort are shown and error bars 
represent SEM. In each case the NPI in the ARID1A mutant cell line was 
significantly less than in the wild-type model, p<0.05 Student’s test. (F) 
Western blot analysis demonstrating YES1 silencing caused by each 
individual siRNA species in the OVISE cell line. The OVISE cell line was 
transfected with either control siRNA, individual YES1 siRNAs, YES1 
SMARTpool or mock transfected. 48 hours following transfection whole cell 
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lysates were collected. Western blot was probed for YES1 and ACTIN was 
included as a loading control. 
 
Figure 4. Dasatinib sensitivity in ARID1A mutant OCCC is characterised 
by G1 arrest and an apoptotic response. (A) Column chart illustrating the 
proportion of cells in different phases of the cell cycle when exposed to 
dasatinib. Exposure to dasatinib led to a significant increase in the proportion 
of cells in the G1 phase of the cell cycle in the ARID1A mutant cell lines 
HCH1 and OVISE but not the ARID1A wild-type cell lines ES2 and KK. Cells 
were exposed to 50 nM dasatinib for 24 hours and fixed in 70% ethanol prior 
to propidium iodide staining and FACS analysis. Error bars represent + SD 
from n = 3 independent experiments. S phase fraction in ARID1A mutant 
tumour cells is significantly reduced by dasatinib exposure (Student’s t-test  
p<0.05, for both OVISE and HCH1). (B) Bar chart illustrating caspase 3/7 
activity in response to dasatinib. Cells were treated as in (A) and caspase 3/7 
activity assessed using the ApoTox Glo triplex assay (Promega). p-values for 
ARID1A mutant cells (OVISE and TOV21G) cells versus ARID1A wild-type 
(ES2 and KK) ***p<0.001, **p<0.01 Student’s t-test.  
 
Figure 5. Dasatinib sensitivity in ARID1A mutant OCCC is dependent 
upon G1/S checkpoint effectors. (A) Drug effect (DE) Z score distribution 
plots from two independent dasatinib resistance siRNA screens in OVISE 
tumour cells. Data from SF50 (left) and SF16 (right) dasatinib resistant screens 
are shown. CDKN1A and RB1 siRNA effects are highlighted, driving dasatinib 
resistance in each screen. (B) Dasatinib dose response curves for the 
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ARID1A mutant OCCC cell line, OVISE and the ARID1A wild-type cell line, 
ES2 following transfection with the CDKN1A siRNA SMARTpool. Silencing of 
CDKN1A expression results in dasatinib resistance. Each point represents the 
mean and SEM of six replicates. CDKN1A siRNA dasatinib survival curve vs. 
control siRNA two-way ANOVA p<0.0001 for OVISE and p=0.02 for ES2.  (C) 
Dasatinib dose response curves for the ARID1A mutant OCCC cell line 
OVISE and the ARID1AQ456*/Q456* isogenic clone following transfection with 
four individual CDKN1A siRNA oligos and the CDKN1A SMARTpool. Each of 
the individual siRNAs results in dasatinib resistance suggesting that the effect 
observed is not due to an off-target effect. For each CDKN1A siRNA dasatinib 
survival curve vs. control siRNA two-way ANOVA p<0.001.(D) Western blot 
demonstrating the on-target nature of the CDKN1A siRNA. OVISE cell line 
was transfected with CDKN1A siRNA and whole cell lysates collected 48 
hours later. Lysates were probed with the p21 antibody and a fluorescent-dye 
labeled secondary antibody used.  
 
Figure 6. In vivo assessment of ARID1A mutant xenograft models. (A) 
Representative IVIS luminescent images of mice with TOV21G peritoneal 
xenografts after 14 days dasatinib treatment. TOV21G cells were infected with 
a luciferase expressing lentivector and injected into the peritoneum of BALB 
athymic mice (n=40). Twenty-four hours later, dasatinib (15 mg/kg/day, n=20) 
or vehicle (n=20) was initiated Ten minutes prior to IVIS imaging, mice were 
administered luciferin (10 ul/mg) intraperitoneally. Coloured bar represents 
photon count/ cm2/sec. (B) Bar chart of mean luminescence values and SEM 
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of photons/cm2/sec. Dasatinib treated vs. vehicle treated, two-way ANOVA p< 
0.01.  
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